Maged Shenouda Purchases 90,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Maged Shenouda bought 90,000 shares of the business’s stock in a transaction on Monday, May 19th. The stock was bought at an average cost of $0.49 per share, for a total transaction of $44,100.00. Following the purchase, the chief financial officer now directly owns 228,335 shares of the company’s stock, valued at approximately $111,884.15. This trade represents a 65.06% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Maged Shenouda also recently made the following trade(s):

• On Tuesday, May 20th, Maged Shenouda bought 60,000 shares of Relmada Therapeutics stock. The shares were bought at an average price of $0.52 per share, with a total value of $31,200.00.
• On Friday, May 16th, Maged Shenouda purchased 50,000 shares of Relmada Therapeutics stock. The stock was purchased at an average price of $0.44 per share, for a total transaction of $22,000.00.

Relmada Therapeutics Stock Up 17.3%

Relmada Therapeutics stock traded up $0.09 during midday trading on Tuesday, hitting $0.60. 1,386,935 shares of the stock were exchanged, compared to its average volume of 913,305. The stock has a market capitalization of $19.82 million, a PE ratio of -0.21 and a beta of 0.18. The company has a fifty day simple moving average of $0.34 and a two-hundred day simple moving average of $0.77. Relmada Therapeutics, Inc. has a 52 week low of $0.24 and a 52 week high of $4.47.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.27). As a group, equities research analysts anticipate that Relmada Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new stake in shares of Relmada Therapeutics in the first quarter worth about $33,000. Renaissance Technologies LLC grew its position in shares of Relmada Therapeutics by 535.5% in the 4th quarter. Renaissance Technologies LLC now owns 164,513 shares of the company’s stock valued at $86,000 after purchasing an additional 138,625 shares during the period. Tang Capital Management LLC increased its stake in Relmada Therapeutics by 295.1% during the 4th quarter. Tang Capital Management LLC now owns 200,825 shares of the company’s stock worth $104,000 after purchasing an additional 150,000 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its holdings in Relmada Therapeutics by 206.5% during the 4th quarter. AdvisorShares Investments LLC now owns 210,068 shares of the company’s stock worth $109,000 after buying an additional 141,540 shares during the period. 45.24% of the stock is currently owned by institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.